[A25-141] Andexanet alfa (acute major bleeding) – Addendum to Project A25-87
Last updated 22.01.2026
Project no.:
A25-141
Commission:
Commission awarded on 12.11.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adult patients treated with a direct factor Xa inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrollable bleeding
Patients with intracerebral haemorrhage: unchanged after addendum: hint of a lesser benefit
All other patients in the therapeutic indication: unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-141
| Project no. | Title | Status |
|---|---|---|
| A25-87 | Andexanet alfa (acute major bleeding) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-12-18 A G-BA decision was published.